C. Ottensmeier, et al. Article available on Nature Communications website – Download the Article
Category: dates
Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
NatCom
Transgene expands myvac®into NSCLC with TG4070
link to webcast
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Mpox WCID
TG4070
TG4070 – Phase 1 trial: Evaluation in Combination with Nivolumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients TG4070 TG4070 is the second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate derived from our proprietary myvac® platform, expanding into non-small cell lung cancer (NSCLC). TG4070 is being evaluated in a Phase 1 trial in combination with… Continue reading TG4070
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
TG4070
Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles
L. Walther, et al. Article available on ISEV website – Download the Article
Robust Protection Against Monkeypox Virus Mediated by a Novel Cell‑Line–Derived MVA Vaccine (TG-MVACL)
N. Silvestre, et al. World Congress on Infectious Diseases WCID 2026 Abstract available on WCID website – Download the abstract – Download the oral presentation
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
MPOX
Transgene’s Combined General Meeting of May 22, 2026
AG 2026